Compare Ascendis Pharma A/S (ASND) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Fiverr International Ltd — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Fiverr International Ltd trades at $8.73 (market cap $314.57M). The key difference: Ascendis Pharma A/S is far larger — about 53× Fiverr International Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | FVRR | |
|---|---|---|
Market Cap | $16.67B | $314.57M |
Sector | Health | Industrials |
52-Week High | $277.18 | $26.67 |
52-Week Low | $189.74 | $8.75 |
Enterprise Value | $17.04B | $66.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Fiverr International (FVRR) trades at $8.66, down 4.73% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation ratios with a P/E of 10.8 and P/S of 0.77, but faces headwinds from AI disruption compressing demand for freelance services. Revenue declined to $97.8 million in Q2 2026 (MarketBeat, July 29, 2026), contributing to a lowered full-year outlook.
The investment outlook is cautious. While valuations appear cheap and the company maintains a strong gross margin of 82%, significant risks from competitive AI technologies and recent execution challenges temper near-term optimism. Analyst consensus leans Hold with a $10.70 price target, suggesting limited upside from current levels amid transitional pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
